Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Key value for chemical safety assessment

Effects on fertility

Description of key information

OECD TG 422, Combined repeated dose oral and reproductive toxicity: NOAEL, fertility: > 250 mg/kg/day (no adverse effects observed)

Link to relevant study records
Reference
Endpoint:
screening for reproductive / developmental toxicity
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
comparable to guideline study
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
GLP compliance:
not specified
Limit test:
no
Species:
rat
Strain:
Sprague-Dawley
Remarks:
Animal supplier: Japan Charles River Astugi Rearing Center, Japan
Sex:
male/female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Age at study initiation: 10 weeks
- Weight at study initiation: males 355.5-405.2 g, females 208.7-255.0 g
- Housing: individually
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 14 days

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21-25°C
- Humidity (%): 40-75%
- Photoperiod (hrs dark / hrs light): 12/12

IN-LIFE DATES: From: 26.05.2005 To: 20.07.2005 (not stated in the report, estimation based on 42 treatment and 14 recovery days)
Route of administration:
oral: gavage
Vehicle:
CMC (carboxymethyl cellulose)
Remarks:
0.5 % Carboxymethyl cellulose sodium [dissolved Japanese Pharmacopoeia Carmellose sodium with Japanese Pharmacopoeia injection solvent]
Details on exposure:
VEHICLE
- Concentration in vehicle: 1.25 % (w/v), 2.5 % (w/v) and 5 % (w/v)
- Amount of vehicle (if gavage): 5 mL/kg
- Justification for choice of vehicle: test material was confirmed to be hardly soluble in the preliminary test

MAXIMUM DOSE VOLUME APPLIED: 5 mL/kg

PREPARATION OF DOSING SOLUTIONS:
A 5 w/v% liquid was prepared by weighing the test material on a balance, after grinding with a mortar, adding small amounts of the solvent medium. This was then serially diluted with the solvent medium.
Details on mating procedure:
- M/F ratio per cage: 1/1
- Length of cohabitation: 2 weeks as maximum
- Proof of pregnancy: confirmation of semen in the vaginal smear or copulatory plug
- After successful mating each pregnant female was caged: separately
Analytical verification of doses or concentrations:
yes
Details on analytical verification of doses or concentrations:
For measurement of the test material concentration in prepared test specimen, 0.5 ml of the respective prepared test specimen was taken, and the test solution was prepared by diluting appropriately with methanol. Separately, the required amount of the test material was weighed and dissolved in methanol, and standard solution was prepared (1, 2, 5 μg/ml). Test solution and standard solution were measured by high performance liquid chromatography (HPLC), and the concentration was obtained by using the calibration curve created from standard solution.
Duration of treatment / exposure:
males: continuous 42 days from 2 weeks before mating through the longest 2-week mating period to the day before autopsy
females: 2 weeks before mating, mating period until copulation, gestation period, and lactation day 4 (42-48days)
females without delivery: until the day before autopsy date (pregnancy 25 days equivalent)
females of the satellite group: continuous to day 42
Frequency of treatment:
once a day, from 9-12 am
Details on study schedule:
- Age at mating of the mated animals in the study: 10 weeks
Dose / conc.:
62.5 mg/kg bw/day (nominal)
Dose / conc.:
125 mg/kg bw/day (nominal)
Dose / conc.:
250 mg/kg bw/day (nominal)
No. of animals per sex per dose:
12 (main study)
5 females (satellite control and high-dose group)

Control animals:
yes, concurrent vehicle
Parental animals: Observations and examinations:
CAGE SIDE OBSERVATIONS: yes
- Time schedule: once daily during rearing and recovery period, 2 times daily before and after administration during administration period

DETAILED CLINICAL OBSERVATIONS: yes
- Time schedule for males: last day of medical inspection, administration days 7, 14, 21, 28, 35, and 42, for recovery group in addition days 7 and 14
- Time schedule for females: last day of medical inspection, administration days 7, 14, 21, 28, 35, and 42, for the case where observation day falls during delivery, observation was on lactation day 0; other delivery cases were observed between lactation day 0 to 4

BODY WEIGHT: yes
- Time schedule for males and females of the satellite group: on administration days 1, 7, 14, 21, 28, 35, and 42, recovery day 1, 7, and 14, and the day of autopsy (the day after the last administration and recovery day 15).
- Time schedule for females: before confirmation of mating on administration days 1, 7, 14, and 21, after confirmation of mating, pregnancy day 0 (confirmation date of mating), 7, 14, and 20, post partum, nursing day 0 (delivery date) and day 4, and the date of autopsy, measured for females undelivered on pregnancy day 0 (confirmation date of mating), 7, 14, 20, and 26 days equivalent

FOOD INTAKE: yes
- Food intake was calculated from measuring the difference between the feed and the residual feed.
- Food intake for males and females of the satellite group on administration days 1-2, 7-8, 14-15, 29-30, 35-36, and 41-42; days 6-7 and 13-14 of recovery
- Food intake for females before mating, administration days 1-2, 7-8, and 14-15, after confirmation of mating, pregnancy days 0-1, 7-8, 14-15, and 20-21, nursing days 3-4
Oestrous cyclicity (parental animals):
- continueous observation of the estrous cycle was conducted until the day before dividing groups and after the start of administration, vaginal smear specimens were prepared every day and the estrous cycle was observed until cohabitation, and mating was confirmed
- estrous cycle was divided into estrus, proestrum, and anestrus, and after the start of administration, the frequency of test animals that changed to other than 4-day interval of estrous cycle was calculated for each group
Sperm parameters (parental animals):
histological examination of testis and epididymidis in all cases
Litter observations:
On nursing day 0, the number of live and dead pups were counted by females and males separately, gender and existence or nonexistence of external malformation were observed.
Postmortem examinations (parental animals):
SACRIFICE
- after 18-22 hours of abstinence from food, followed by lethal exsanguination under pentobarbital sodium anesthesia or blood collection, autopsy was conducted, and hematologic test, biochemical examination of blood, and pathology examination were performed

GROSS NECROPSY
- Macroscopic observation of organs and tissues were performed for all cases at autopsy
- Collection and storage of organs in case of lesions: brain, hypophysectomy, medulla, heart, airway tube, lung (includes bronchial tubes),liver, kidney, asymmetric thymus, spleen, adrenal gland, thyroid, stomach, duodenum, jejunum, ileum, cecum, colon, rectum, testis, epididymidis, ventral prostate, seminal vesicles including coagulating glands, ovaries, uterus, vagina, bladder, mandible lymph nodes, mesenteric lymph nodes, sciatic nerve, femora, and bone marrow

HISTOPATHOLOGY / ORGAN WEIGHTS
- Histological examination was conducted for ovaries, testis, and epididymidis of all cases, iin cases where changes were observed macroscopically, of appropriate test animals, and for organs and tissues other than these of the respective 5 cases, for which hematologic test and biochemical examination of blood were performed, from the control group and 250 mg/kg group of males for autopsy at the completion of administration and of female delivery cases
- Organ weights (actual weight): brain, heart, asymmetric thymus, liver, kidney, spleen, adrenal gland, ovary, and epididymidis
Postmortem examinations (offspring):
GROSS NECROPSY
- among newborn pups, necropsies on dead pups were immediately performed and preserved
- necropsies were performed on all cases of newborn pups after lethal sacrifice by inhalation of ether day 4 of nursing
Statistics:
Concerning frequency and fertility index of test animals with change of estrous cycle, Fisher's exact probability test was conducted (significance level: 5%) from histological examination findings of the test material administered groups, a significance test was conducted between the control group with the data sorted out by grade by Mann-Whitney U test (significance level: 5%) and with the total values of positive grades by Fisher’s exact probability one-sided test (significance level: 5%).
For other data, values obtained for each individual or average-value by every litter were made into a specimen and compared within the satellite and other groups. At this point, when the object of analysis was 2 groups, F test was first conducted, and if significant difference was not identified, Student’s t test was conducted. When a significant difference was identified by F test, the Aspin-Welch test was then performed. When the object of analysis was more than 3 groups, a test was conducted on uniformity of dispersion of the respective group by the Bartlett method (significance level: 5%). When the dispersion was uniform, one-way analysis of variance (significance level 5%) was performed, and when significance was identified among groups, multiple comparisons were made by the Dunnett method (significance level 5%).On the other hand, when dispersion in any of the groups was 0 and dispersion was not uniform, the Kruskal-Wall rank order test (significance level: 5%) was performed, and when significance was recognized, multiple comparisons were made by the Dunnett test method (significance level: 5%).
Reproductive indices:
- birth rate of each group [(number of females delivering live births/number of pregnant test animals) x 100%]
- rate of implantation [(number of implantations / number of pregnant corpora lutea) x 100%], calculated from the number of implantations and number of pregnant corpora lutea observed during autopsy of nursing day 5
Offspring viability indices:
- delivering rate (number of pups/number of implantation mark) x 100%]
- live birth rate [(number of delivered live birth/number of implantation mark) x 100%]
- birth rate [(number of delivered live birth/number of pups) x 100%]
- newborn survival rate[(number of live pups on nursing day 4/number of live pups on nursing day 0 ) x 100%]
- individual body weight of live pups was measured on nursing day 0 and 4, average value was calculated for each litter, by male and female separately
- gender ratio on nursing day 0 and 4 [(number of male live birth/total number of live birth)] x 100%]
Clinical signs:
effects observed, treatment-related
Description (incidence and severity):
Auricular black spot, purple-black tail tip, tail node, auricular tubercle, scrotum hardening, scrotum nodule were observed in females and males of the 250 mg/kg dose group and seen also in continuous withdrawal.
Mortality:
mortality observed, treatment-related
Description (incidence):
One male (dead on 8th day of administration) and one female (dead on 1st day of nursing) animal of the 250 mg/kg bw/day group died throughout the study. Change in clinical symptoms was not observed before the death of the male case, but since congestion and edema in lung were identified in histopathology, the cause of death seems to be respiratory depression. In female death, incomplete eyelid opening and tabefaction the day after delivery were followed and confirmed by death, and though the stress of delivery could have induced incidence of death, a wide range of necrosis in proximal tubule of cortex of kidney was identified by histopathology.
Body weight and weight changes:
effects observed, treatment-related
Description (incidence and severity):
In regard to body weight trend, remarkable weight gain was identified with males of the 250 mg/kg dose group, the same changes, could be seen with the same group females of the satellite group, but the changes vanished along with withdrawal. Lower feed intake quantity was identified with males of the 250 mg/kg dose group, the same changes, could be seen with the same group females of the satellite group, but the changes vanished along with withdrawal.
Haematological findings:
effects observed, treatment-related
Description (incidence and severity):
With males of the 250 mg/kg dose group, the hematocrit value with hematologic test was lowered significantly in serum albumin concentration with the biochemical examination of blood.
Clinical biochemistry findings:
effects observed, treatment-related
Description (incidence and severity):
At the completion of the administration period in the test, albumin concentration in the blood in males of the 62.5 and 250 mg/kg dosage groups lowered significantly, compared with the control group; moreover, creatinine concentration in males of the 250 mg/kg dosage group was lowered significantly. At the completion of the recovery period in the test, creatinine concentration in males and females of the 250 mg/kg dosage group, compared with the control group, was lowered significantly. Moreover, triglyceride level in females of the 250 mg/kg dosage group increased significantly compared with the control the group.
Urinalysis findings:
effects observed, treatment-related
Description (incidence and severity):
With males of the 250 mg/kg dose group, a high frequency of erythrocytes in urine were identified.
Behaviour (functional findings):
no effects observed
Immunological findings:
not examined
Organ weight findings including organ / body weight ratios:
effects observed, treatment-related
Histopathological findings: non-neoplastic:
effects observed, treatment-related
Description (incidence and severity):
Multinucleated giant cell in subcutaneous tissue was observed together with granuloma and inflammatory cell infiltration. With histological examination of kidney, very slight edema of the papilla was identified in males of the 62.5 mg/kg dose group and females of the 250 mg/kg dose group (only at the end of recovery period), and lipofuscin of the proximal tubule was identified for both females (very slight to slight) and males (slight to moderate) of the 62.5 mg/kg dose group. With histological examination of adrenal glands in males, diffuse enlargement of cortical cells adhesion was identified with the administration groups above 62.5 mg/kg. Changes described above in the kidney and adrenal gland was also identified in animals after withdrawal.
Histopathological findings: neoplastic:
no effects observed
Reproductive function: oestrous cycle:
no effects observed
Description (incidence and severity):
No influence of the test material administration could be identified in the estrous cycle, copulation rate, birth rate, pregnancy period, and delivering rate.
Reproductive function: sperm measures:
no effects observed
Description (incidence and severity):
In histological examination of testes and epididymidis, seminiferous tubule atrophy and intraductal cell debris in males other than the infertile cases are seen, but they are localized and the change is mild and does not suggest toxicity of the test material.
Reproductive performance:
effects observed, treatment-related
Description (incidence and severity):
Three cases of infertility evidenced in the 250 mg/kg dose group and the number of corpora lutea for the same group was reduced significantly compared to the control group, but significant change in the rate of implantation was not identified. However, no clear influence was seen in oestrous cycle, and abnormality was also not observed in ovaries; therefore, whether a decrease of number of corpora lutea was induced by administration of the test material or not could not be determined. All cases of pregnant females gave live births and no significant difference was observed between the control group and the TTC respective dosage group during gestation period.
Dose descriptor:
LOEL
Effect level:
62.5 mg/kg bw/day (nominal)
Based on:
test mat.
Sex:
male/female
Basis for effect level:
other: pigmentation in the proximal tubule of kidney and diffuse enlargement of the adrenal cortex in dose groups above 62.5 mg/kg bw/day
Dose descriptor:
NOEL
Effect level:
125 mg/kg bw/day (nominal)
Based on:
test mat.
Sex:
female
Basis for effect level:
other: infertility was identified in the 250 mg/kg bw/day dose group
Dose descriptor:
NOAEL
Effect level:
125 mg/kg bw/day (nominal)
Based on:
test mat.
Sex:
male/female
Basis for effect level:
other: auricular black spot, purple-black tail tip, tail node, auricular tubercle, scrotum hardening, scrotum noduleauricular black spot, purple-black tail tip, tail node, auricular tubercle, scrotum hardening, scrotum nodule
Critical effects observed:
yes
Lowest effective dose / conc.:
250 mg/kg bw/day (nominal)
Organ:
skin
Treatment related:
yes
Dose response relationship:
not specified
Relevant for humans:
not specified
Clinical signs:
no effects observed
Mortality / viability:
no mortality observed
Description (incidence and severity):
With regard to survival of pups no change suggesting the influence of administration of the test material was seen.
Body weight and weight changes:
no effects observed
Description (incidence and severity):
Regarding the body weight of pups, no influence of administration of the test material on change in the average body weight of the groups was observed. Decreased weight gain in one litter of the 250 mg/kg dose group was identified, but this dam animal showed tabefaction during nursing, and abnormality in kidney, asymmetric thymus, and stomach in histological examination was observed; therefore, decrease in lactation volume along with deterioration of general condition of dam animal seems to be the cause.
Sexual maturation:
not examined
Organ weight findings including organ / body weight ratios:
not examined
Gross pathological findings:
no effects observed
Description (incidence and severity):
Furthermore, concerning morphology of pups, abnormality was not observed in morphological observation of deaths and 0-day nursing, and further, during autopsy of 4-day nursing; thus, this test material does not influence development growth and differentiation of pups.
In the 250 mg/kg dosage group, whitish nodule was observed on the body surface of nursing pups observed after the death of dam animal, but the change was only in 1 litter, and no abnormality was observed in 0-day nursing; thus, findings did not originate from administration of the test material.
Histopathological findings:
not examined
Dose descriptor:
NOAEL
Generation:
F1
Sex:
male/female
Remarks on result:
not determinable due to absence of adverse toxic effects
Reproductive effects observed:
not specified
Conclusions:
The LOEL for the toxicity of repeated trithiocyanuric acid administration under the conditions of this study was determined to be 62.5mg/kg/day for both females and males based on edema in papilla combined with pigmentation of cortex in proximal tubule of the kidenys. Based on the presence of auricular black spot, purple-black tail tip, tail node, auricular tubercle, scrotum hardening, scrotum nodule in females and males of the 250 mg/kg dose group and seen also in continuous withdrawal the NOAEL of 125 mg/kg bw/day was derived. The NOAEL for reproductive toxicity was determined to be > 250 mg/kg/day due to no advers effects on reproduction. No adverse toxicological effects in pups were reported, therfore the NOAEL for F1 generation is determined to be > 250 mg/kg/day.
Effect on fertility: via oral route
Endpoint conclusion:
no adverse effect observed
Study duration:
subacute
Species:
rat
Quality of whole database:
Guideline studies according to OECD TGs are available (reliable without restrictions).
Effect on fertility: via inhalation route
Endpoint conclusion:
no study available
Effect on fertility: via dermal route
Endpoint conclusion:
no study available
Additional information

OECD TG 422, Combined repeated dose oral and reproductive toxicity:

Female and male rats underwent repeated oral administration with dosages of 0 (solvent control), 62.5, 125 and 250 mg/kg trithiocyanuric acid to study toxicity of reapeted dosing and influence on the reproduction and birthing in parent animals and pup development. The LOEL for the toxicity of repeated trithiocyanuric acid administration under the conditions of this study was determined to be 62.5mg/kg/day for both females and males, and the NOAEL for reproductive toxicity was determined to be > 250 mg/kg/day. In the absence of adverse toxicological effects the NOAEL for F1 generation is > 250 mg/kg/day. In the 250 mg/kg dosage group, 3 cases out of 12 cases were identified with infertility, but all cases in other administered groups were pregnant; thus, influence of the test material on fertility is doubtful. With regard to survival of pups no change suggesting the influence of administration of the test material was seen. Regarding the body weight of pups, no influence of administration of the test material on change in the average body weight of the groups was observed. Furthermore, concerning development of pups, abnormality was not observed in morphological observation of deaths and 0-day nursing, and further, during autopsy of 4-day nursing; thus, this test material does not influence development growth and differentiation of pups.

Effects on developmental toxicity

Effect on developmental toxicity: via oral route
Endpoint conclusion:
no study available
Effect on developmental toxicity: via inhalation route
Endpoint conclusion:
no study available
Effect on developmental toxicity: via dermal route
Endpoint conclusion:
no study available

Justification for classification or non-classification

Based on the available information and in the absence of adverse toxicological effects on reproduction Trithiocyanuric acid is not classified according to CLP Regulation (EC) No 1272/2008.

Additional information